Editorial Director, Addiction & Recovery · Last reviewed January 2025
Opioid use disorder (OUD) is a significant public health crisis in the United States. CDC data indicates that drug overdose deaths exceeded 107,000 in 2023, with synthetic opioids — primarily illicitly manufactured fentanyl — driving the overwhelming majority of deaths. Fentanyl is 50–100 times more potent than morphine, dramatically increasing overdose risk even with small exposure variations.
The Opioid Receptor System
Opioids act on mu-opioid receptors in the brain, spinal cord, and periphery. Mu-receptor activation produces analgesia, euphoria, respiratory depression, and constipation. The reward signal drives escalating use; physical dependence develops through receptor downregulation and adaptation. The euphoric effect diminishes with tolerance while physical dependence and cravings persist — the core mechanism of the addiction cycle.
Recognizing and Responding to Overdose
Opioid overdose is characterized by the clinical triad of unconsciousness, respiratory depression, and miosis (pinpoint pupils). Any bystander can administer naloxone (Narcan) — available without prescription in all states — which reverses opioid overdose by displacing opioids from receptors. Given fentanyl's potency, multiple doses of naloxone may be required. Call 911 immediately and administer naloxone while waiting for emergency services. Most states have Good Samaritan laws providing immunity from drug possession prosecution when calling 911 for an overdose.
Opioid Withdrawal
Opioid withdrawal, while intensely uncomfortable, is rarely life-threatening in otherwise healthy adults. It begins 8–24 hours after last use of short-acting opioids (heroin, oxycodone) or 36–72 hours for methadone, and peaks at 36–72 hours for short-acting opioids. Symptoms include anxiety, yawning, diaphoresis, lacrimation, rhinorrhea, goosebumps, muscle aches, nausea, vomiting, diarrhea, and insomnia. The discomfort is a major driver of relapse without pharmacological support.
Evidence-Based Treatment: MAT
The National Academies of Sciences, Engineering, and Medicine's 2020 report concludes that MAT reduces overdose mortality by 50% or more and improves virtually all treatment-relevant outcomes. The three FDA-approved medications:
- Buprenorphine (Suboxone, Sublocade) — Partial opioid agonist; high efficacy; can be prescribed in office-based settings; the X-waiver requirement was eliminated in 2023, expanding prescriber access significantly
- Methadone — Full opioid agonist; dispensed through federally certified OTPs; longest evidence base; most effective for severe OUD; requires daily clinic attendance initially
- Extended-release naltrexone (Vivitrol) — Opioid antagonist; monthly injection; no abuse potential; requires complete detoxification before initiation
MAT is not "trading one drug for another" — it is evidence-based medical treatment that normalizes neurobiological function, eliminates withdrawal, reduces cravings, and blocks the effects of illicitly used opioids. SAMHSA, ASAM, and the National Academies all recommend MAT as the standard of care for OUD.
Related: MAT Full Guide · Opioid Addiction & Mental Health · PTSD & Addiction